Buscar en
Avances en Diabetología
Toda la web
Inicio Avances en Diabetología Metformina y acidosis láctica: ¿asociación infrecuente o causalidad?
Información de la revista
Vol. 26. Núm. 4.
Páginas 273-275 (Agosto - Agosto 2010)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
3753
Vol. 26. Núm. 4.
Páginas 273-275 (Agosto - Agosto 2010)
Tema de actualidad
DOI: 10.1016/S1134-3230(10)64015-X
Acceso a texto completo
Metformina y acidosis láctica: ¿asociación infrecuente o causalidad?
Metformin and lactic acidosis: infrequent association or causality?
Visitas
...
F. Carral San Laureano
Autor para correspondencia
florencarral@hotmail.com

F. Carral San Laureano. Unidad de Gestión Clínica de Endocrinología y Nutrición. Hospital Universitario Puerto Real. Carretera Nacional IV, km 665. 11510 Puerto Real (Cádiz).
, M.C. Ayala Ortega
Unidad de Gestión Clínica de Endocrinología y Nutrición. Hospital Universitario Puerto Real. Cádiz
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Lista de acrónimos citados en el texto
cLDL

colesterol unido a las lipoproteínas de baja densidad

DPP

Diabetes Prevention Program

GPC

guía de práctica clínica

HbA1c

hemoglobina glucosilada

UKPDS

United Kingdom Prospective Diabetes Study.

Texto completo
WARNING preg_replace(): Unknown modifier 'p' (includes_ws_v2/librerias/utilidades.php[398])
Bibliografía
[1.]
D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferranini, R.R. Holman, R. Sherwin, et al.
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy.
Diabetes Care., 32 (2009), pp. 1-11
[2.]
National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. Available on: http://www.nice.org.uk.
[3.]
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee.
Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Can J Diabetes., 32 (2008), pp. 53-61
[4.]
A. Sáenz, I. Fernández, A. Mataix, M. Ausejo, M. Roqué, D. Moher.
Metformina para la diabetes mellitus tipo 2.
Revisión sistemática y metaanálisis. Aten Primaria., 36 (2005), pp. 183-193
[5.]
Diabetes Prevention Program Research Group, W.C. Knowler, S.E. Fowler, R.F. Hamman, C.A. Christophi, H.J. Hoffman, et al.
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Lancet., 374 (2009), pp. 1677-1686
[6.]
R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil.
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med., 359 (2008), pp. 1577-1589
[7.]
I. Tzoulaki, M. Molokhia, V. Curcin, M.P. Little, C.J. Millett, A. Ng, et al.
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetic drugs: retrospective cohort study using UK general practice research database.
BMJ., 339 (2009), pp. b4731
[8.]
S. Bolen, L. Feldman, J. Vassy, L. Wilson, H.C. Yeh, S. Marinopoulos, et al.
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
Ann Intern Med., 147 (2007), pp. 386-399
[9.]
A.D. Wright, C.A. Cull, K.M. Macleod, R.R. Holman, for the UKPDS Group.
Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73.
J Diabetes Complications., 20 (2006), pp. 395-401
[10.]
J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, A.D. Morris.
Metformin and reduced risk of cancer in diabetic patients.
BMJ., 330 (2005), pp. 1304-1305
[11.]
G. Libby, L.A. Donnelly, P.T. Donnan, D.R. Alessi, A.D. Morris, J.M. Evans.
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
Diabetes Care., 32 (2009), pp. 1620-1625
[12.]
C.J. Currie, C.D. Poole, E.A. Gale.
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Diabetologia., 52 (2009), pp. 1766-1777
[13.]
S.L. Bowker, S.R. Majumdar, P. Veugelers, J.A. Johnson.
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Diabetes Care., 29 (2006), pp. 254-258
[14.]
S. Jiralerspong, S.L. Palla, S.H. Giordano, F. Meric-Bernstam, C. Liedtke, C.M. Barnett, et al.
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
J Clin Oncol., 27 (2009), pp. 3297-3302
[15.]
E.G. Lebacq, A. Tirzmalis.
Metformin and lactic acidosis.
[16.]
D. Luft, R.M. Schmülling, M. Eggstein.
Lactic acidosis in biguanide-treated diabetics: a review of 330 cases.
Diabetologia., 14 (1978), pp. 75-87
[17.]
R. Rachmani, I. Slavachevski, Z. Levi, B. Zadok, Y. Kedar, M. Ravid.
Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications.
Eur J Intern Med., 13 (2002), pp. 428
[18.]
J.B. Brown, K. Pedula, J. Barzilay, M.K. Herson, P. Latare.
Lactic acidosis rates in type 2 diabetes.
Diabetes Care., 21 (1998), pp. 1659-1663
[19.]
J.V. Selby, B. Ettinger, B.E. Swain, J.B. Brown.
First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization.
Diabetes Care., 22 (1999), pp. 38-44
[20.]
R.R. Holman, C.A. Cull, R.C. Turner, UKPDS Group.
A randomized double-blind trial of acarbose in type ii diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44).
Diabetes Care., 22 (1999), pp. 960-964
[21.]
S.R. Salpeter, E. Greyber, G.A. Pasternak, E.E. Salpeter Posthumous.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Cochrane Database Syst Rev, (2010),
[22.]
S. Salpeter, E. Greyber, G. Pasternak, E. Salpeter.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Cochrane Database Syst Rev, (2003),
[23.]
A.A. Tahrani, G.I. Varughese, J.H. Scarpello, F.W. Hanna.
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?.
[24.]
A.I. Duncan, C.G. Koch, M. Xu, M. Manlapaz, B. Batdorf, G. Pitas.
Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery.
Anesth Analg., 104 (2007), pp. 42-50
[25.]
S.K. Goergen, G. Rumbold, G. Compton, C. Harris.
Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin.
Radiology., 254 (2010), pp. 261-269
[26.]
A.M. Stades, J.T. Heikens, D.W. Erkelens, F. Holleman, J.B. Hoekstra.
Metformin and lactic acidosis: cause or coincidence? A review of case reports.
J Intern Med., 255 (2004), pp. 179-187
[27.]
J.D. Lalau, J.M. Race.
Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations.
Drug Saf., 20 (1999), pp. 377-384
Copyright © 2010. AVDIAB
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.